Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
Director John Paulson reported purchasing 34,721,118 shares of Bausch Health Companies Inc. (NASDAQ:BHC) on August 14, 2025. The shares were bought at a price of $9.0, totaling approximately $312,490,062. The stock, currently trading at $7.51, has shown remarkable momentum with a 30% surge in the past week. According to InvestingPro analysis, BHC is currently trading near its Fair Value.
Following the transaction, Paulson’s managed funds indirectly hold 70,755,869 shares of Bausch Health Companies Inc. The pharmaceutical company, with a market capitalization of $2.77 billion, maintains a GREAT financial health score according to InvestingPro analysis. Discover 8 additional key insights about BHC and access comprehensive Pro Research Reports, available exclusively with an InvestingPro subscription.
In other recent news, Bausch Health Companies Inc reported second-quarter earnings that significantly exceeded analyst expectations. The company posted adjusted earnings per share of $0.40, far surpassing the analyst consensus of $0.04. Revenue for the quarter reached $2.53 billion, beating estimates of $2.48 billion and marking a 5% increase from $2.40 billion in the same quarter last year. These results have led to a positive response from investors, as the company also provided an upbeat outlook. No recent mergers or acquisitions were reported for Bausch Health. Additionally, there have been no recent analyst upgrades or downgrades for the company. These developments highlight the company’s strong financial performance and positive investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.